Warner Chilcott plc. is a specialty pharmaceutical company focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the North American and Western European pharmaceuticals markets. It is an integrated company with internal resources focused to the development, manufacture and promotion of its products. It has acquired a number of products through license, co-promotion arrangements or purchase, including ASACOL, ACTONEL, ENABLEX, ESTRACE Cream, FEMHRT and LOESTRIN. On October 8, 2010, Food & Drug Administration (FDA) approved ATELVIA product for the treatment of postmenopausal osteoporosis in the United States. On October 21, 2010, FDA approved LO LOESTRIN FE product for the prevention of pregnancy in the United States. On December 22, 2010, FDA approved WC3026 product for the prevention of pregnancy in the United States.